Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection

Zhang,Qingqing; Xu,Mingyi; Qu,Ying; Li,Zhenghong; Zhang,Qidi; Cai,Xiaobo; Lu,Lungen

doi:10.3892/mmr.2015.4221

Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection

Authors:
- Qingqing Zhang
- Mingyi Xu
- Ying Qu
- Zhenghong Li
- Qidi Zhang
- Xiaobo Cai
- Lungen Lu
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiao‑Tong University School of Medicine, Shanghai 200080, P.R. China
Published online on: August 12, 2015 https://doi.org/10.3892/mmr.2015.4221
Pages: 5647-5654
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Considering the limitations of liver biopsy, reliable non‑invasive serum biomarkers of liver fibrosis are required for early diagnosis. The present study analyzed the expression profile of circulating micro (mi)RNAs during the development and progression of hepatic fibrosis in patients with chronic hepatitis B virus (HBV) infection, aiming to identify novel earlier diagnostic biomarkers. Fresh plasma samples were collected from 50 patients diagnosed with chronic HBV infection and hepatic fibrosis. These patients were classified into five groups (S0, S1, S2, S3 and S4; n=10 per group) based on Scheuer's staging criteria. The differential expression of the circulating miRNAs was determined by performing miRNA microarray hybridization. Finally, the target genes of the miRNAs were predicted and classified using gene ontology analysis. A total of 140 miRNAs were detected in the S1‑S4 patient groups, and their expression levels were >2‑fold higher compared with those in the S0 group. The numbers of miRNAs differentially expressed in the S1‑S4 patient groups were 48, 97, 84 and 56, respectively, with 12 miRNAs differentially expressed at all stages, 10 of which were upregulated and two of which were downregulated. The target genes of the miRNAs identified were found to be involved in 100 signal transduction pathways, the majority of which affected hepatic fibrosis via the TGF‑/Smad, Wnt, MAPK, Jak/STAT and VEGF pathways. The differential expression levels of miRNAs were closely associated with the staging of hepatic fibrosis. The results of the present study provide evidence to facilitate the development and application of non‑invasive biomarkers for earlier diagnosis of hepatic fibrosis.

View Figures

View References

1	Hou J, Liu Z and Gu F: Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2:502005. View Article : Google Scholar : PubMed/NCBI
2	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
3	Vettori S, Gay S and Distler O: Role of MicroRNAs in Fibrosis. Open Rheumatol J. 6:130–139. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K and Kaneko S: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 49:1098–1112. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wang XW, Heegaard NH and Orum H: MicroRNAs in liver disease. Gastroenterology. 142:1431–1443. 2012. View Article : Google Scholar : PubMed/NCBI
6	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association: The guidelines of prevention and treatment for chronic hepatitis B. Chin J Hepatol. 13:881–891. 2005.In Chinese.
7	Scheuer PJ: The nomenclature of chronic hepatitis: Time for a change. J Hepatol. 22:112–114. 1995. View Article : Google Scholar : PubMed/NCBI
8	Audic S and Claverie JM: The significance of digital gene expression profiles. Genome Res. 7:986–995. 1997.PubMed/NCBI
9	Mar JC, Kimura Y, Schroder K, Irvine KM, Hayashizaki Y, Suzuki H, Hume D and Quackenbush J: Data-driven normalization strategies for high-throughput quantitative RT-PCR. BMC Bioinformatics. 10:1102009. View Article : Google Scholar : PubMed/NCBI
10	Park JH, Yoon J, Lee KY and Park B: Effects of geniposide on hepatocytes undergoing epithelial-mesenchymal transition in hepatic fibrosis by targeting TGFβ/Smad and ERK-MAPK signaling pathways. Biochimie. 113:26–34. 2015. View Article : Google Scholar : PubMed/NCBI
11	Qu W, Huang H, Li K and Qin C: Danshensu-mediated protective effect against hepatic fibrosis induced by carbon tetrachloride in rats. Pathol Biol (Paris). 62:348–353. 2014. View Article : Google Scholar
12	Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, Moser CD, Shaleh HM, Thornburgh SR, Walters I and Roberts LR: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS One. 9:e922732014. View Article : Google Scholar : PubMed/NCBI
13	Li J, Li X, Xu W, Wang S, Hu Z, Zhang Q, Deng X, Wang J, Zhang J and Guo C: Antifibrotic effects of luteolin on hepatic stellate cells and liver fibrosis by targeting AKT/mTOR/p70S6K and TGFβ/Smad signalling pathways. Liver Int. 35:1222–1233. 2015. View Article : Google Scholar
14	Zhou K and Lu LG: Assessment of fibrosis in chronic liver diseases. J Dig Dis. 10:7–14. 2009. View Article : Google Scholar : PubMed/NCBI
15	Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM and Rodés J: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 36:986–992. 2002. View Article : Google Scholar : PubMed/NCBI
16	Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y and Poynard T; MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet. 357:1069–1075. 2001. View Article : Google Scholar : PubMed/NCBI
17	Song Y, Wang F, Huang Q, Cao Y, Zhao Y and Yang C: MicroRNAs contribute to hepatocellular carcinoma. Mini Rev Med Chem. 15:459–466. 2015. View Article : Google Scholar : PubMed/NCBI
18	Park K and Kim KB: miRTar Hunter: A prediction system for identifying human microRNA target sites. Mol Cells. 35:195–201. 2013. View Article : Google Scholar : PubMed/NCBI
19	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
21	Kim T and Reitmair A: Non-Coding RNAs: Functional aspects and diagnostic utility in oncology. Int J Mol Sci. 14:4934–4968. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu Z, Zhou X, Chen L, et al: Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem. 56:1871–1879. 2010. View Article : Google Scholar : PubMed/NCBI
24	Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 47:784–791. 2011. View Article : Google Scholar
25	Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut. 58:1375–1381. 2009. View Article : Google Scholar : PubMed/NCBI
26	Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M and Sun S: Plasma microRNA-122 as a biomarker for viral-, alcohol- and chemical-related hepatic diseases. Clin Chem. 56:1830–1838. 2010. View Article : Google Scholar : PubMed/NCBI
27	Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, et al: Circulating MicroRNAs, miR-21, miR-122 and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 50:136–142. 2011. View Article : Google Scholar : PubMed/NCBI
28	Choo KB, Soon YL, Nguyen PN, Hiew MS and Huang CJ: MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci. 21:952014. View Article : Google Scholar : PubMed/NCBI
29	Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK and Hsieh TY: Hepatitis C virus core protein down-regulates p21Waf1/Cip1 and inhibits curcumin-induced apoptosis through microRNA-345 targeting in human hepatoma cells. PloS One. 8:e610892013. View Article : Google Scholar :
30	Li G, Qiu Y, Su Z, Ren S, Liu C, Tian Y and Liu Y: Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. PLoS One. 8:e844862013. View Article : Google Scholar : PubMed/NCBI
31	Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, Liu X and Liu Z: Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS One. 8:e666762013. View Article : Google Scholar : PubMed/NCBI
32	Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P and Bechara FG: Expression of microRNAs in basal cell carcinoma. Brit J Dermatol. 167:847–855. 2012. View Article : Google Scholar
33	Kanda T, Ishibashi O, Kawahigashi Y, Mishima T, Kosuge T, Mizuguchi Y, Shimizu T, Arima Y, Yokomuro S, Yoshida H, et al: Identification of obstructive jaundice-related microRNAs in mouse liver. Hepatogastroenterology. 57:1013–1023. 2010.
34	Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A and Yakhini Z: Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One. 4:e80032009. View Article : Google Scholar : PubMed/NCBI
35	Song L, Lin C, Gong H, Wang C, Liu L, Wu J, Tao S, Hu B, Cheng SY, Li M, et al: miR-486 sustains NF-kappaB activity by disrupting multiple NF-kappaB-negative feedback loops. Cell Res. 23:274–289. 2013. View Article : Google Scholar :
36	Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One. 8:e601552013. View Article : Google Scholar : PubMed/NCBI
37	Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 32:1910–1920. 2013. View Article : Google Scholar :
38	Yadav S, Pandey A, Shukla A, Talwelkar SS, Kumar A, Pant AB and Parmar D: miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. J Biol Chem. 286:37347–37357. 2011. View Article : Google Scholar : PubMed/NCBI